Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 9,255,000 shares as part of its 2022 Share Award Scheme, representing approximately 0.1009% of the total shares in issue. This move is part of the company’s strategic objective to strengthen its market position in the medical aesthetics and biopharmaceutical industries, potentially enhancing its operational capabilities and stakeholder value.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is an international pharmaceutical and medical aesthetic company listed on the Main Board of The Stock Exchange of Hong Kong Limited since 2010. The company is driven by innovation with a strong research and development platform, a diverse global product pipeline, and efficient production capabilities. It aims to be a leader in the medical aesthetics and biopharmaceutical sectors in China.
Average Trading Volume: 81,615,751
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.93B
See more data about 0460 stock on TipRanks’ Stock Analysis page.